The Intergroupe Francophone du Myélome experience with thalidomide


https://doi.org/10.4081/hmr.v1i11.352
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
Published: June 5, 2009
Abstract Views: 153
PDF: 252
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The Intergroupe Francophone du Myélome (IFM) has conducted studies of thalidomide as treatment for relapsed or refractory multiple myeloma (MM) and as first-line therapy. One study comparing two doses of thalidomide (100 vs 400 mg/d) in relapsed patients has not yet been analyzed. Another study testing low-dose thalidomide in combination with melphalan and prednisone (MP) in elderly patients (>75 years) with newly diagnosed MM is ongoing. Three studies are presented here. Of these, one phase 2 study in relapsed/refractory patients has already been published; the other two have been presented in meetings only.

Supporting Agencies


Harousseau, J.-L., Attal, M., Facon, T., & Yakoub-Agha, I. (2009). The Intergroupe Francophone du Myélome experience with thalidomide. Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.352
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC